Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban
This article was originally published in The Pink Sheet Daily
Unable to find a partner to co-develop the compound, Astellas is bowing out of the anticoagulant space.
You may also be interested in...
More so than any other big pharma, Merck is dependent on large outcomes trials. The cost of failure is high, but success would allow entry into massive, highly generic primary care markets with products backed by clinical outcomes data that meet payers’ need for real-world evidence of a drug’s value in terms of health economics as well as clinical efficacy.
Without a partner for its anticoagulant in an increasingly complex market, privately-held Portola takes $89 million in late-stage money to conduct Phase III trials on its own.
Daiichi Sankyo's Edoxaban Enters Its First Market; Eisai "Very Pleased" With Eribulin Japanese Price Listing
TOKYO - Drugmakers introduced a number of new products in Japan this week, including the first launch globally of Daiichi Sankyo Co. Ltd.'s oral factor Xa inhibitor edoxaban, following the release of National Health Insurance price listings